Compare BigBearai Holdings Inc (BBAI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs TG Therapeutics Inc — how do they compare? BigBearai Holdings Inc trades at $3.27 (market cap $1.60B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 4.8× BigBearai Holdings Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBAI | TGTX | |
|---|---|---|
Market Cap | $1.60B | $7.64B |
Sector | Technology | Health |
52-Week High | $8.91 | $59.06 |
52-Week Low | $2.61 | $26.94 |
Enterprise Value | $1.30B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.26, up 0.93% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 revenue growth of 13% but missed EPS expectations, continuing negative profitability trends. Recent news highlights defense contract wins and generative AI platform expansion, while analyst consensus remains cautious with 75% hold ratings.
The outlook remains challenging with persistent losses and negative cash flow projections for 2026. Investment opportunity lies in defense AI specialization and backlog growth, but risks include execution challenges, high valuation multiples, and dependence on government contracts. The stock requires careful monitoring of profitability improvements.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
